DexTech Medical ABXSAT:DEX -0.49%17 EV-to-FCF is -134.06 as of Jul. 04, 2026. GuruFocus rates XSAT:DEX with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 332 Biotechnology companies, DexTech Medical AB ranks worse than 301204.52% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, DexTech Medical AB's Enterprise Value is kr178.44 Mil.
DexTech Medical AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr-1.33 Mil. Therefore, DexTech Medical AB's EV-to-FCF for today is -134.06.
The historical rank and industry rank for DexTech Medical AB's EV-to-FCF or its related term are showing as below:
XSAT:DEX'
s EV-to-FCF Range Over the Past 10 Years
Min: -1583.83 Med: -319.69 Max: -24.84
Current: -139.62
During the past 13 years, the highest EV-to-FCF of DexTech Medical AB was -24.84. The lowest was -1583.83. And the median was -319.69.
XSAT:DEX's EV-to-FCF is ranked worse than 100% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs XSAT:DEX: -139.62
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DexTech Medical AB (XSAT:DEX) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DexTech Medical AB's PE Ratio (TTM) for today is calculated as:
DexTech Medical AB's share price for today is kr10.20.
DexTech Medical AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
DexTech Medical AB EV-to-FCF Related Terms
DexTech Medical AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for DexTech Medical AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:DEX vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, DexTech Medical AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexTech Medical AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DexTech Medical AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where DexTech Medical AB's EV-to-FCF falls into.
DexTech Medical AB's current Enterprise Value is kr178.44 Mil.
DexTech Medical AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DexTech Medical AB (XSAT:DEX) has a EV-to-FCF of -134.06 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on DexTech Medical AB and its competitors. According to the industry distribution chart, DexTech Medical AB ranks #999999 out of 332 companies in the Biotechnology industry.
Is DexTech Medical AB's EV-to-FCF too high?
DexTech Medical AB's current EV-to-FCF is -134.06. Based on the distribution chart, DexTech Medical AB ranks #999999 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DexTech Medical AB has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DexTech Medical AB ranks #999999 out of 332 companies for EV-to-FCF. This places DexTech Medical AB in the lower half of its industry. The industry median EV-to-FCF is 16.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on DexTech Medical AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexTech Medical AB's current EV-to-FCF is -134.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current EV-to-FCF of -134.06. The current EV-to-FCF is -134.06. DexTech Medical AB's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current EV-to-FCF is -134.06 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
17GF Score
Get the complete analysis for XSAT:DEX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:DEX has been successfully added to your 
